APLS vs PODD · rev $781.4M vs P/E 34, rev $2.07B
Apellis Pharmaceuticals Inc (APLS) versus Insulet Corporation (PODD) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Insulet Corporation (PODD) is a medical devices company listed on NASDAQ.
Latest reported APLS revenue for 2024-12-31 was $781.4M. Net income was -$197.9M. Revenue was up 97.0% from 2023-12-31 to 2024-12-31. APLS currently screens at market cap $2.29B.
Latest reported PODD revenue for 2024-12-31 was $2.07B. Net income was $418.3M. Revenue was up 22.1% from 2023-12-31 to 2024-12-31. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
APLS currently screens at market cap $2.29B. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
Not investment advice. Open the APLS and PODD stock pages for the full models.
Not investment advice.